TR200706209T1 - Alfuzosinin kontrollü salınım formülasyonları. - Google Patents

Alfuzosinin kontrollü salınım formülasyonları.

Info

Publication number
TR200706209T1
TR200706209T1 TR2007/06209T TR200706209T TR200706209T1 TR 200706209 T1 TR200706209 T1 TR 200706209T1 TR 2007/06209 T TR2007/06209 T TR 2007/06209T TR 200706209 T TR200706209 T TR 200706209T TR 200706209 T1 TR200706209 T1 TR 200706209T1
Authority
TR
Turkey
Prior art keywords
controlled release
alfuzosin
release formulations
treatment
pharmaceutical formulation
Prior art date
Application number
TR2007/06209T
Other languages
English (en)
Turkish (tr)
Inventor
Niccolai Fabrizio
Ravelli Vittorino
Original Assignee
Ph&T Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ph&T Spa filed Critical Ph&T Spa
Publication of TR200706209T1 publication Critical patent/TR200706209T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
TR2007/06209T 2005-03-11 2006-03-06 Alfuzosinin kontrollü salınım formülasyonları. TR200706209T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000391A ITMI20050391A1 (it) 2005-03-11 2005-03-11 Formulazioni a rilascio controllato di alfuzosin

Publications (1)

Publication Number Publication Date
TR200706209T1 true TR200706209T1 (tr) 2007-12-24

Family

ID=36939083

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2007/06209T TR200706209T1 (tr) 2005-03-11 2006-03-06 Alfuzosinin kontrollü salınım formülasyonları.

Country Status (6)

Country Link
KR (1) KR20070110068A (xx)
CN (1) CN101137351A (xx)
IT (1) ITMI20050391A1 (xx)
RU (1) RU2423107C2 (xx)
TR (1) TR200706209T1 (xx)
WO (1) WO2006094736A2 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
CN101095681B (zh) * 2007-07-13 2011-04-20 沈阳药大制剂新技术有限公司 盐酸阿夫唑嗪渗透泵型控释制剂及其制备方法
CN105287422A (zh) * 2015-12-07 2016-02-03 黑龙江省智诚医药科技有限公司 一种盐酸阿夫唑嗪缓释片及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
PT938318E (pt) * 1996-08-29 2001-10-30 Jagotec Ag Comprimido com libertacao controlada de cloridrato de alfuzosina
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu

Also Published As

Publication number Publication date
KR20070110068A (ko) 2007-11-15
ITMI20050391A1 (it) 2006-09-12
CN101137351A (zh) 2008-03-05
RU2007133793A (ru) 2009-03-20
RU2423107C2 (ru) 2011-07-10
WO2006094736A3 (en) 2007-01-04
WO2006094736A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
BRPI0814102A2 (pt) Implante pélvico, e, kit.
IL209494A (en) Formulations of insulin oligomeric monoconogues and their use
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
DK1723128T3 (da) Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
DK1753406T4 (da) Overtrukket tabletformulering og fremgangsmåde
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
DE602006004731D1 (de) Trockengranulierungzusammensetzung enthaltend Emtricitabine und Tenofovir DF
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EA200801430A1 (ru) Производные триазола
EP1731609A4 (en) INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
NO20081292L (no) Pentasykliske kinaseinhibitorer
HK1127995A1 (en) Phaseolus vulgaris extracts, their use, and formulations containing them
BRPI0615630A2 (pt) composição farmacêutica, e, uso de sertindol
TR200706209T1 (tr) Alfuzosinin kontrollü salınım formülasyonları.
ATE417560T1 (de) Chirurgischer nagel